ALK G1202R

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
ALK G1202R AND v::ALK Fusion	Crizotinib	Predictive	C	Supports Resistance	3	accepted	EID1357 A patient with ALK-rearranged lung adenocarcinoma responded to crizotinib treatment and then had relapse. Biopsy was taken within half a month and total DNA was extracted from the sample. Exons 20-28,… (full text at CIViC) PMID 22277784 · Katayama et al., 2012 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma6
ALK G1202R AND v::ALK Fusion	Crizotinib	Predictive	C	Supports Resistance	1	submitted	EID4624 In a non-small cell lung cancer patient with acquired crizotinib resistance, the tumor had an ALK gene rearrangement and an ALK G1202R co-mutation. The ALK G1202R tumor was reported to be refractory t… (full text at CIViC) PMID ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Lung Adenocarcinoma1

ALK G1202R AND v::ALK Fusion

Crizotinib

Predictive

Supports Resistance

accepted

EID1357

A patient with ALK-rearranged lung adenocarcinoma responded to crizotinib treatment and then had relapse. Biopsy was taken within half a month and total DNA was extracted from the sample. Exons 20-28,… (full text at CIViC)

PMID 22277784 · Katayama et al., 2012 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma6

ALK G1202R AND v::ALK Fusion

Crizotinib

Predictive

Supports Resistance

submitted

EID4624

In a non-small cell lung cancer patient with acquired crizotinib resistance, the tumor had an ALK gene rearrangement and an ALK G1202R co-mutation. The ALK G1202R tumor was reported to be refractory t… (full text at CIViC)

PMID ·

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376134	Uncertain significance	criteria provided, multiple submitters, no conflicts	2	Lung cancer; Neuroblastoma, susceptibility to, 3; Hereditary cancer-predisposing syndrome	germline/somatic	4	Aug 19, 2025	clinvar

Variation

Clinical significance

Review status

Stars

Conditions

Origin

Submitters

Last evaluated

Source

376134

Uncertain significance

criteria provided, multiple submitters, no conflicts

Lung cancer; Neuroblastoma, susceptibility to, 3; Hereditary cancer-predisposing syndrome

germline/somatic

Aug 19, 2025

clinvar

Malignant Neoplasm5
EML4::ALK Fusion AND ALK G1202R	Alectinib	Predictive	D	Supports Resistance	3	accepted	EID1350 Ba/F3 cell line expressing EML4-ALK variant 3 with G1202R ALK mutation was assessed for alectinib sensitivity and IC50 for survival of 868 nM was reported, which was 64.4x higher than the IC50 reporte… (full text at CIViC) PMID 25727400 · Fontana et al., 2015 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1202R	Brigatinib	Predictive	D	Supports Resistance	3	accepted	EID1351 This study compared drug responses in Ba/F3 cells expressing either EML4-ALK or NPM-ALK fusions, with or without G1202R ALK mutation. Cells expressing the EML4-ALK variant 3 with G1202R ALK mutation w… (full text at CIViC) PMID 25727400 · Fontana et al., 2015 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1202R	Lorlatinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID7593 Ba/F3 cells expressing the EML4-ALK fusion with the G1202R resistance mutation were sensitive to lorlatinib in a cell viability assay. However, cells expressing variant 1 of EML4-ALK (E13; A20) had sl… (full text at CIViC) PMID 29650534 · Yoda et al., 2018 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1202R AND ALK L1196M	Alectinib + Brigatinib + Ceritinib + Crizotinib + LorlatinibSubstitutes	Predictive	D	Supports Resistance	4	submitted	EID7592 EML4-ALK expressing Ba/F3 cell lines with the compound ALK mutation G1202R/L1196M were found to be resistant to lorlatinib as well as first and second-line ALK inhibitors. H3122 lung cancer cell lines… (full text at CIViC) PMID 29650534 · Yoda et al., 2018 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1202R AND ALK L1198F	Alectinib + Brigatinib + Ceritinib + LorlatinibSubstitutes	Predictive	D	Supports Resistance	4	submitted	EID7595 EML4-ALK expressing Ba/F3 cell lines with the compound ALK mutation G1202R/L1198F were found to be resistant to lorlatinib as well as second-line ALK inhibitors. Ba/F3 cells expressing variant 1 (E13;… (full text at CIViC) PMID 29650534 · Yoda et al., 2018 · Open in CIViC	civic

Malignant Neoplasm5

EML4::ALK Fusion AND ALK G1202R

Alectinib

Predictive

Supports Resistance

accepted

EID1350

Ba/F3 cell line expressing EML4-ALK variant 3 with G1202R ALK mutation was assessed for alectinib sensitivity and IC50 for survival of 868 nM was reported, which was 64.4x higher than the IC50 reporte… (full text at CIViC)

PMID 25727400 · Fontana et al., 2015 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1202R

Brigatinib

Predictive

Supports Resistance

accepted

EID1351

This study compared drug responses in Ba/F3 cells expressing either EML4-ALK or NPM-ALK fusions, with or without G1202R ALK mutation. Cells expressing the EML4-ALK variant 3 with G1202R ALK mutation w… (full text at CIViC)

PMID 25727400 · Fontana et al., 2015 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1202R

Lorlatinib

Predictive

Supports Sensitivity Response

submitted

EID7593

Ba/F3 cells expressing the EML4-ALK fusion with the G1202R resistance mutation were sensitive to lorlatinib in a cell viability assay. However, cells expressing variant 1 of EML4-ALK (E13; A20) had sl… (full text at CIViC)

PMID 29650534 · Yoda et al., 2018 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1202R AND ALK L1196M

Alectinib + Brigatinib + Ceritinib + Crizotinib + LorlatinibSubstitutes

Predictive

Supports Resistance

submitted

EID7592

EML4-ALK expressing Ba/F3 cell lines with the compound ALK mutation G1202R/L1196M were found to be resistant to lorlatinib as well as first and second-line ALK inhibitors. H3122 lung cancer cell lines… (full text at CIViC)

PMID 29650534 · Yoda et al., 2018 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1202R AND ALK L1198F

Alectinib + Brigatinib + Ceritinib + LorlatinibSubstitutes

Predictive

Supports Resistance

submitted

EID7595

EML4-ALK expressing Ba/F3 cell lines with the compound ALK mutation G1202R/L1198F were found to be resistant to lorlatinib as well as second-line ALK inhibitors. Ba/F3 cells expressing variant 1 (E13;… (full text at CIViC)

PMID 29650534 · Yoda et al., 2018 · Open in CIViC

civic

Pleural Malignant Mesothelioma1
EML4::ALK Fusion AND ALK G1202R AND ALK I1171N AND ALK L1196M	Lorlatinib	Predictive	C	Supports Resistance	3	accepted	EID11114 This case report describes a 33 year-old non-smoker with no known exposure to asbestos who was diagnosed with stage IIIB malignant pleural mesothelioma. Panel next generation sequencing (NGS) of 520 g… (full text at CIViC) PMID 32600123 · Hu et al., 2020 · Open in CIViC	civic

Pleural Malignant Mesothelioma1

EML4::ALK Fusion AND ALK G1202R AND ALK I1171N AND ALK L1196M

Lorlatinib

Predictive

Supports Resistance

accepted

EID11114

This case report describes a 33 year-old non-smoker with no known exposure to asbestos who was diagnosed with stage IIIB malignant pleural mesothelioma. Panel next generation sequencing (NGS) of 520 g… (full text at CIViC)

PMID 32600123 · Hu et al., 2020 · Open in CIViC

civic

Evidence by cancer (13 items)

Clinical significance (1)